MedTrace Logo

Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

NCT06717204 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2024-12-04

No results posted yet for this study

Summary

The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.

Conditions

  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • Myocardial Infarction (MI)

Interventions

DRUG

Vericiguat Oral Tablet [Verquvo]

Vericiguat in addition to conventional treatment

DRUG

Prescription Drugs

Conventional treatment only

Sponsors & Collaborators

  • Jinan Central Hospital

    collaborator OTHER

  • Qianfoshan Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Panpan Hao, MD, PhD · Qilu Hospital of Shandong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717204 on ClinicalTrials.gov